Delivery Order SPE2DB20D1110-SPE2DB24FK32T

Award Date 6/24/24
Potential Completion Date 6/25/24
Potential Value $3.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 45 MG TABLET. The contract, valued at $13,727.88, is a firm-fixed price delivery order with an ultimate completion date of August 1, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,840.18 firm fixed-price delivery order is for the supply of RINVOQ ER 15 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of March 10, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $51,407.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of RINVOQ ER 15 MG TABLET, a pharmaceutical product. It is a firm fixed-price, delivery order contract with an ultimate completion date of April 30, 2025. The contract is not designated as a set-aside and was openly competed. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of RINVOQ ER 30 MG TABLET UU 30S. The $3,216.14 firm fixed price delivery order has a completion date of June 18, 2025. The contract is not set aside and is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award is a Delivery Order valued at $7,024.41 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is for the supply of RINVOQ ER 15 MG TABLET medical tablets. The contract has an ultimate completion date of February 4, 2025 and utilizes a Firm Fixed Price pricing type. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 30 MG TABLET. The contract, valued at $15,784.85, is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical, a part of the U.S. Department of Defense. The contract is a firm fixed price agreement with an ultimate completion date of September 18, 2024. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and...
This federal contract award, valued at $7,659.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 15 MG TABLET, a pharmaceutical product, with a completion date of May 29, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of RINVOQ ER 45 MG TABLET. The contract has a ceiling value of $43,301.23 and a completion date of October 17, 2024. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $7,552.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of RINVOQ ER 15 MG TABLET, a prescription medication. The contract has an ultimate completion date of February 26, 2025 and is a Firm Fixed Price arrangement. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,962.91 firm fixed-price delivery order is for RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of March 7, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
  • SPE2DB20D1110
    Indefinite Delivery Contract
  • SPE2DB20D1110-SPE2DB24FK32T
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the supply of RINVOQ ER 15 MG TABLET. The contract has a ceiling value of $3,741.63 and is a Firm Fixed Price Delivery Order with a completion date of June 25, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating it was awarded on a full and open competition basis.

Generated 9/23/24, 10:12 AM